Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours

Abstract

Individuals with germline mutations in the tumour-suppressor gene CYLD are at high risk of developing disfiguring cutaneous appendageal tumours, the defining tumour being the highly organised cylindroma. Here, we analysed CYLD mutant tumour genomes by array comparative genomic hybridisation and gene expression microarray analysis. CYLD mutant tumours were characterised by an absence of copy-number aberrations apart from LOH chromosome 16q, the genomic location of the CYLD gene. Gene expression profiling of CYLD mutant tumours showed dysregulated tropomyosin kinase (TRK) signalling, with overexpression of TRKB and TRKC in tumours when compared with perilesional skin. Immunohistochemical analysis of a tumour microarray showed strong membranous TRKB and TRKC staining in cylindromas, as well as elevated levels of ERK phosphorylation and BCL2 expression. Membranous TRKC overexpression was also observed in 70% of sporadic BCCs. RNA interference-mediated silencing of TRKB and TRKC, as well as treatment with the small-molecule TRK inhibitor lestaurtinib, reduced colony formation and proliferation in 3D primary cell cultures established from CYLD mutant tumours. These results suggest that TRK inhibition could be used as a strategy to treat tumours with loss of functional CYLD.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  • Adly MA, Assaf HA, Nada EA, Soliman M, Hussein M . (2005). Human scalp skin and hair follicles express neurotrophin-3 and its high-affinity receptor tyrosine kinase C, and show hair cycle-dependent alterations in expression. Br J Dermatol 153: 514–520.

    Article  CAS  Google Scholar 

  • Alvarez-Rodríguez R, Barzi M, Berenguer J, Pons S . (2007). Bone morphogenetic protein 2 opposes Shh-mediated proliferation in cerebellar granule cells through a TIEG-1-based regulation of Nmyc. J Biol Chem 282: 37170–37180.

    Article  Google Scholar 

  • Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. (2007). Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115–130.

    Article  CAS  Google Scholar 

  • April C, Klotzle B, Royce T, Wickham-Garcia E, Boyaniwsky T, Izzo J et al. (2009). Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS One 4: e8162.

    Article  Google Scholar 

  • Arévalo JC, Waite J, Rajagopal R, Beyna M, Chen Z-Y, Lee FS et al. (2006). Cell survival through Trk neurotrophin receptors is differentially regulated by ubiquitination. Neuron 50: 549–559.

    Article  Google Scholar 

  • Blasing H, Hendrix S, Paus R . (2005). Pro-inflammatory cytokines upregulate the skin immunoreactivity for NGF, NT-3, NT-4 and their receptor, p75NTR in vivo: a preliminary report. Arch Dermatol Res 296: 580–584.

    Article  Google Scholar 

  • Bowen S, Gill M, Lee DA, Fisher G, Geronemus RG, Vazquez ME et al. (2005). Mutations in the CYLD gene in Brooke–Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: lack of genotype–phenotype correlation. J Invest Dermatol 124: 919–920.

    Article  CAS  Google Scholar 

  • Bruckner-Tuderman L, Pfaltz M, Schnyder UW . (1991). Cylindroma overexpresses collagen VII, the major anchoring fibril protein. J Invest Dermatol 96: 729–734.

    Article  CAS  Google Scholar 

  • Brummelkamp TR, Nijman SM, Dirac AM, Bernards R . (2003). Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424: 797–801.

    Article  CAS  Google Scholar 

  • Butti MG, Bongarzone I, Ferraresi G, Mondellini P, Borrello MG, Pierotti MA . (1995). A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics 28: 15–24.

    Article  CAS  Google Scholar 

  • Chen-Tsai CP, Colome-Grimmer M, Wagner RF . (2004). Correlations among neural cell adhesion molecule, nerve growth factor, and its receptors, TrkA, TrkB, TrkC, and p75, in perineural invasion by basal cell and cutaneous squamous cell carcinomas. Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery (et al) 30: 1009–1016.

    Google Scholar 

  • Coe BP, Ylstra B, Carvalho B, Meijer GA, Macaulay C, Lam WL . (2007). Resolving the resolution of array CGH. Genomics 89: 647–653.

    Article  CAS  Google Scholar 

  • Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM . (2010). Classical and/or alternative NF B pathway activation in multiple myeloma. Blood 115: 3541–3552.

    Article  CAS  Google Scholar 

  • Donovan J . (2009). Review of the hair follicle origin hypothesis for basal cell carcinoma. Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery (et al) 35: 1311–1323.

    Article  CAS  Google Scholar 

  • Dunning MJ, Barbosa-Morais NL, Lynch AG, Tavaré S, Ritchie ME . (2008). Statistical issues in the analysis of Illumina data. BMC Bioinformatics 9: 85.

    Article  Google Scholar 

  • Dutton R, Yamada T, Turnley A, Bartlett PF, Murphy M . (1999). Regulation of spinal motoneuron differentiation by the combined action of Sonic hedgehog and neurotrophin 3. Clin Exp Pharmacol Physiol 26: 746–748.

    Article  CAS  Google Scholar 

  • Gao J, Huo L, Sun X, Liu M, Li D, Dong JT et al. (2008). The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem 283: 8802–8809.

    Article  CAS  Google Scholar 

  • Geetha T, Jiang J, Wooten MW . (2005). Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling. Mol Cell 20: 301–312.

    Article  CAS  Google Scholar 

  • Geetha T, Seibenhener ML, Chen L, Madura K, Wooten MW . (2008). p62 serves as a shuttling factor for TrkA interaction with the proteasome. Biochem Biophys Res Commun 374: 33–37.

    Article  CAS  Google Scholar 

  • Gerretsen AL, van der Putte SC, Deenstra W, van Vloten WA . (1993). Cutaneous cylindroma with malignant transformation. Cancer 72: 1618–1623.

    Article  CAS  Google Scholar 

  • Gunnarsson R, Staaf J, Jansson M, Ottesen AM, Goransson H, Liljedahl U et al. (2008). Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia—a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 47: 697–711.

    Article  CAS  Google Scholar 

  • Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R, Bosserhoff AK . (2007). Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28: 21–27.

    Article  CAS  Google Scholar 

  • Hoseong Yang S, Andl T, Grachtchouk V, Wang A, Liu J, Syu L et al. (2008). Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/β-catenin signaling. Nat Genet 40: 1130–1135.

    Article  Google Scholar 

  • Huang EJ, Reichardt LF . (2001). Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24: 677–736.

    Article  CAS  Google Scholar 

  • Illumina Inc. (2009). Beadstudio Gene Expression Module v3.4 User Guide (113172615 Rev A) Illumina Inc.: San Diego, CA.

  • Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D et al. (2007). Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 110: 3291–3300.

    Article  CAS  Google Scholar 

  • Jin W, Yun C, Kim H-S, Kim S-J . (2007). TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling. Cancer Res 67: 9869–9877.

    Article  CAS  Google Scholar 

  • Kavanagh DO, Chambers G, O'Grady L, Barry KM, Waldron RP, Bennani F et al. (2009). Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 9: 1.

    Article  Google Scholar 

  • Keats J, Fonseca R, Chesi M, Schop R, Baker A, Chng W et al. (2007). Promiscuous mutations activate the noncanonical NF-κB Pathway in multiple myeloma. Cancer Cell 12: 131–144.

    Article  CAS  Google Scholar 

  • Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y et al. (2008). Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer 123: 552–560.

    Article  CAS  Google Scholar 

  • Komander D, Lord CJ, Scheel H, Swift S, Hofmann K, Ashworth A et al. (2008). The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell 29: 451–464.

    Article  CAS  Google Scholar 

  • Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G . (2003). The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424: 801–805.

    Article  CAS  Google Scholar 

  • Kriegl L, Horst D, Kirchner T, Jung A . (2009). LEF-1 expression in basal cell carcinomas. Br J Dermatol 160: 1353–1356.

    Article  CAS  Google Scholar 

  • Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R et al. (2009). TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 28: 1960–1970.

    Article  CAS  Google Scholar 

  • Lamb J . (2006). The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929–1935.

    Article  CAS  Google Scholar 

  • Liu H-H, Xie M, Schneider MD, Chen ZJ . (2006). Essential role of TAK1 in thymocyte development and activation. Proc Natl Acad Sci USA 103: 11677–11682.

    Article  CAS  Google Scholar 

  • Luo J, Solimini NL, Elledge SJ . (2009). Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823–837.

    Article  CAS  Google Scholar 

  • Marchio C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS et al. (2008). The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 216: 399–407.

    Article  CAS  Google Scholar 

  • Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N et al. (2005). Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 23: 31–37.

    Article  CAS  Google Scholar 

  • Martin-Zanca D, Hughes SH, Barbacid M . (1986). A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 319: 743–748.

    Article  CAS  Google Scholar 

  • Massoumi R . (2006). Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-κB signaling. Cell 125: 665–677.

    Article  CAS  Google Scholar 

  • Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R . (2006). Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125: 665–677.

    Article  CAS  Google Scholar 

  • Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T et al. (2009). Downregulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 206: 221–232.

    Article  CAS  Google Scholar 

  • Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ . (1995). Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 55: 1798–1806.

    CAS  PubMed  Google Scholar 

  • Meybehm M, Fischer HP . (1997). Spiradenoma and dermal cylindroma: comparative immunohistochemical analysis and histogenetic considerations. Am J Dermatopathol 19: 154–161.

    Article  CAS  Google Scholar 

  • Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P et al. (2010). Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol 79: 1272–1280.

    Article  CAS  Google Scholar 

  • Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DSP et al. (2009). An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 121: 575–589.

    Article  Google Scholar 

  • Nilsson M, Undèn AB, Krause D, Malmqwist U, Raza K, Zaphiropoulos PG et al. (2000). Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci USA 97: 3438–3443.

    Article  CAS  Google Scholar 

  • Oosterkamp HM, Neering H, Nijman SM, Dirac AM, Mooi WJ, Bernards R et al. (2006). An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. Br J Dermatol 155: 182–185.

    Article  CAS  Google Scholar 

  • Qiao W, Li AG, Owens P, Xu X, Wang X-J, Deng C-X . (2006). Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin. Oncogene 25: 207–217.

    Article  CAS  Google Scholar 

  • Rajan N, Langtry JAA, Ashworth A, Roberts C, Chapman P, Burn J et al. (2009). Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction. Arch Dermatol 145: 1277–1284.

    Article  CAS  Google Scholar 

  • Reiley WW, Jin W, Lee AJ, Wright A, Wu X, Tewalt EF et al. (2007). Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med 204: 1475–1485.

    Article  CAS  Google Scholar 

  • Reiley W, Zhang M, Sun S-C . (2004). Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem 279: 55161–55167.

    Article  CAS  Google Scholar 

  • Reiley WW, Zhang M, Jin W, Losiewicz M, Donohue KB, Norbury CC et al. (2006). Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol 7: 411–417.

    Article  CAS  Google Scholar 

  • Ricci A, Greco S, Mariotta S, Felici L, Bronzetti E, Cavazzana A et al. (2001). Neurotrophins and neurotrophin receptors in human lung cancer. Am J Respir Cell Mol Biol 25: 439–446.

    Article  CAS  Google Scholar 

  • Saggar S, Chernoff KA, Lodha S, Horev L, Kohl S, Honjo RS et al. (2008). CYLD mutations in familial skin appendage tumours. J Med Genet 45: 298–302.

    Article  CAS  Google Scholar 

  • Saha RN, Liu X, Pahan K . (2006). Upregulation of BDNF in astrocytes by TNF-alpha: a case for the neuroprotective role of cytokine. J Neuroimmune Pharmacol 1: 212–222.

    Article  Google Scholar 

  • Saini HS, Gorse KM, Boxer LM, Sato-Bigbee C . (2004). Neurotrophin-3 and a CREB-mediated signaling pathway regulate Bcl-2 expression in oligodendrocyte progenitor cells. J Neurochem 89: 951–961.

    Article  CAS  Google Scholar 

  • Scala S, Wosikowski K, Giannakakou P, Valle P, Biedler JL, Spengler BA et al. (1996). Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res 56: 3737–3742.

    CAS  PubMed  Google Scholar 

  • Shabbir M, Stuart R . (2010). Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Invest Drugs 19: 427–436.

    Article  CAS  Google Scholar 

  • Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ . (2007). The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci USA 104: 8869–8874.

    Article  CAS  Google Scholar 

  • Stokes A, Wakano C, Koblan-Huberson M, Adra CN, Fleig A, Turner H . (2006). TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. Cell Signal 18: 1584–1594.

    Article  CAS  Google Scholar 

  • Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545–15550.

    Article  CAS  Google Scholar 

  • Suzuki R, Shimodaira H . (2006). Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22: 1540–1542.

    Article  CAS  Google Scholar 

  • Tan DS, Lambros MB, Natrajan R, Reis-Filho JS . (2007). Getting it right: designing microarray (and not ‘microawry’) comparative genomic hybridization studies for cancer research. Lab Invest 87: 737–754.

    Article  CAS  Google Scholar 

  • Tauriello DVF, Haegebarth A, Kuper I, Edelmann MJ, Henraat M, Canninga-van Dijk MR et al. (2010). Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell 37: 607–619.

    Article  CAS  Google Scholar 

  • Teh M-T, Blaydon D, Chaplin T, Foot NJ, Skoulakis S, Raghavan M et al. (2005). Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res 65: 8597–8603.

    Article  CAS  Google Scholar 

  • Tellechea O, Reis JP, Ilheu O, Baptista AP . (1995). Dermal cylindroma. An immunohistochemical study of thirteen cases. Am J Dermatopathol 17: 260–265.

    Article  CAS  Google Scholar 

  • Thress K, Macintyre T, Wang H, Whitston D, Liu ZY, Hoffmann E et al. (2009). Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther 8: 1818–1827.

    Article  CAS  Google Scholar 

  • Timpl R, Fujiwara S, Dziadek M, Aumailley M, Weber S, Engel J . (1984). Laminin, proteoglycan, nidogen and collagen IV: structural models and molecular interactions. Ciba Found Symp 108: 25–43.

    CAS  PubMed  Google Scholar 

  • Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G . (2003). CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424: 793–796.

    Article  CAS  Google Scholar 

  • Trompouki E, Tsagaratou A, Kosmidis SK, Dollé P, Qian J, Kontoyiannis DL et al. (2009). Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia 11: 469–476.

    Article  CAS  Google Scholar 

  • Tunggal L, Ravaux J, Pesch M, Smola H, Krieg T, Gaill F et al. (2002). Defective laminin 5 processing in cylindroma cells. Am J Pathol 160: 459–468.

    Article  CAS  Google Scholar 

  • Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R et al. (2010). Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29: 2013–2023.

    Article  CAS  Google Scholar 

  • Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT . (2000). Rational basis for Trk inhibition therapy for prostate cancer. Prostate 45: 140–148.

    Article  CAS  Google Scholar 

  • Workman C, Jensen LJ, Jarmer H, Berka R, Gautier L, Nielser HB et al. (2002). A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol 3: research0048.

    Article  Google Scholar 

  • Wu C, Ramirez A, Cui B, Ding J, Delcroix J-DM, Valletta JS et al. (2007). A functional dynein-microtubule network is required for NGF signaling through the Rap1/MAPK pathway. Traffic 8: 1503–1520.

    Article  CAS  Google Scholar 

  • Zhang J, Stirling B, Temmerman ST, Ma CA, Fuss IJ, Derry JMJ et al. (2006). Impaired regulation of NF-κB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest 116: 3042–3049.

    Article  CAS  Google Scholar 

  • Zhong S, Fields CR, Su N, Pan Y-X, Robertson KD . (2007). Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26: 2621–2634.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was funded in part by grants from the Newcastle Healthcare Charities Trust, the North East Skin Research Fund, Breakthrough Breast Cancer, Cancer Research UK and the Medical Research Council. N Rajan is a MRC Clinical Training Fellow.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N Rajan.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rajan, N., Elliott, R., Clewes, O. et al. Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours. Oncogene 30, 4243–4260 (2011). https://doi.org/10.1038/onc.2011.133

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2011.133

Keywords

This article is cited by

Search

Quick links